trending Market Intelligence /marketintelligence/en/news-insights/trending/x5EqZ5321ku4xtZ8lxzu6w2 content esgSubNav
In This List

Roche chief medical officer to retire; Lilly exec tapped as successor

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roche chief medical officer to retire; Lilly exec tapped as successor

Roche Holding AG said Sandra Horning will retire on Dec. 31 as chief medical officer and head of global product development of the company and its unit Genentech Inc.

Levi Garraway will succeed Horning as of Oct. 1. Garraway, who will be based in South San Francisco, Calif., was most recently Eli Lilly and Co.'s senior vice president, oncology research and development and Lilly Research Laboratories' novel target research.

Horning joined the Swiss drugmaker in 2009 as senior vice president, global head of clinical science/oncology and hematology in the product development organization. She has been chief medical officer since January 2014.